20th Jul 2022 12:04
Poolbeg Pharma PLC - London-based pharmaceutical company - Receives approval to commence its Lipopolysaccharide human clinical trial for POLB 011, a drug that aims to treat severe influenza. The trial will formally start on Friday. It will assess POLB 011 in damping the immune response to lipopolysaccharide, which acts as a surrogate for the hyperinflammatory response associated with severe influenza. Initial results are expected in the final quarter of 2022. Poolbeg says at that point it intends to "rapidly" monetise by out-licensing and/or partnering with pharmaceutical and biotechnology companies for the drug's further development.
Current stock price: 5.07 pence, up 4.6% in London on Wednesday
12-month change: down 52%
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Poolbeg Pharma